| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Radiation Therapy, Michael Reese Hospital, Chicago, Illinois
Today, a central problem in the treatment of patients with early Hodgkin's disease is the question as to whether or not treatment of areas of known involvement only gives better, the same, or worse survival as a function of time than does treatment of all nodal areas on the involved side of the diaphragm. The reasons for believing that this question can be answered best by a prospective randomized clinical trial are presented. The criteria of evaluation will include survival as a function of time, the time and site of next appearance of disease, and an evaluation of the Karnofsky performance index for patients in the 2 groups. An appendix outlines in detail the statistical considerations underlying the number of patients probably necessary to arrive at an orderly answer to the question.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |